Key result
Prior HFrEF in acute pulmonary embolism is linked to ~2.2-fold higher 7-day mortality.
Why the study?
It was unknown whether the risk of short-term mortality differs in acute pulmonary embolism patients with heart failure with reduced ejection fraction compared to those with heart failure with preserved ejection fraction.
Does heart failure with reduced ejection fraction increase the risk of 7-day mortality in patients with acute pulmonary embolism compared to those with preserved ejection fraction or no heart failure?
Cohort (n=1,055)
Yes
Does heart failure with reduced ejection fraction increase the risk of 7-day mortality in patients with acute pulmonary embolism compared to those with preserved ejection fraction or no heart failure?
This study demonstrates that pre-existing HFrEF, but not HFpEF, independently increases the risk of early intrahospital mortality in patients with acute pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Prior HFrEF may flag higher early mortality risk in acute PE; extends risk stratification data but leaves open prospective validation and management impact.
AIMS: This study aimed to investigate whether the risk of short-term mortality is different in pulmonary embolism (PE) patients who have heart failure with reduced ejection fraction (HFrEF) as compared with those with heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: Predictive value of HFrEF or HFpEF for 7-day (intrahospital) and 30-day all-cause mortality was determined in the cohort of 1055 out of 1201 consecutive acute PE patients from the Serbian multicentre PE registry. Patients were classified into either HFrEF or HFpEF group, according to guideline-proposed criteria. A 7-day (intrahospital) and 30-day all-cause mortality was 18.5% vs. 7.3% vs. 4.5% (P < 0.001) and 22.2% vs. 16.3% vs. 7.9% (P < 0.001) for patients with the history of HFrEF, HFpEF, and without HF, respectively. Multivariable analysis adjusted to age, gender, history of chronic obstructive pulmonary disease, diabetes mellitus, arterial hypertension, presence of atrial fibrillation, and mortality risk assessment at admission has shown that only HFrEF, but not HFpEF, was an independent predictor for 7-day mortality (hazard ratio 2.22, 95% confidence interval 1.25-4,38.41, P = 0.021) and neither HFrEF or HFpEF was an independent predictor for 30-day mortality. Among various admission parameters associated to PE outcome, only systolic pressure in HFrEF patients (P < 0.001), heart rate (P = 0.01), and right ventricle systolic pressure (P = 0.039) in HFpEF patients were significantly different in patients who died compared with those who survived at 7 days. CONCLUSIONS: Our study has shown that the presence of previous history of HFrEF, but not HFpEF, in acute PE is an independent risk factor for mortality at 7 days.
No takes yet. Share an insight, caveat, or question.
Obradović et al. (2020) conducted a cohort in Acute Pulmonary Embolism (n=1,055). Heart failure with reduced ejection fraction (HFrEF) vs. Absence of heart failure or heart failure with preserved ejection fraction (HFpEF) was evaluated on 7-day (intrahospital) all-cause mortality (HR 2.22, 95% CI 1.12-4.38, p=0.021). The presence of a previous history of HFrEF, but not HFpEF, in patients with acute pulmonary embolism was an independent predictor for 7-day mortality (HR 2.22).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: